Researchers at the Spanish National Center for Cardiovascular Research (CNIC) have identified a new target that may open new avenues into pulmonary hypertension (PH) treatment. Their findings were published in Science Advances on Jan. 19, 2024.
Researchers from Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have discovered novel selective Kv2.1 inhibitors as potential therapeutic candidates for the treatment of ischemic stroke.
Collagen prolyl 4-hydroxylase (P4H) is an α-ketoglutarate (α-KG)-dependent dioxygenase, and prolyl 4-hydroxylase subunit α1 (P4HA1) is the major isoform among the catalytic subunits of P4H. It has been previously demonstrated that P4HA1 promotes angiogenesis in tumors, and bioinformatics analysis has identified P4HA1 as a glycolysis-related gene in various cancers.
E-Therapeutics plc has offered a pipeline update, following the nomination of novel target genes, which have yielded promising results in preclinical studies.
Researchers from Shenzhen Salubris Pharmaceuticals Co. Ltd. have published preclinical data for the angiotensin receptor neprilysin (ARN) inhibitor S-086, currently in clinical development for the treatment of hypertension.
University of Ottawa has synthesized ferroptosis inhibitors reported to be useful for the treatment of cancer, diabetes, myocardial infarction, amyotrophic lateral sclerosis, sepsis, shock, transplant rejection and Alzheimer’s dementia.
There is a strong relationship between heart failure (HF) and atrial fibrillation (AF): half of the patients with HF acquire AF. Recent studies discovered a genetic basis underlying AF, which demonstrated a strong heritable component to this disease.
Pulmonary arterial hypertension (PAH), characterized by vasoconstriction and pulmonary vascular remodeling, has a 10% annual mortality rate among patients due to right heart failure. There are genetic variants known to impact the risk of PAH, but susceptibility from epigenetic changes is poorly understood.
RSS
